GoAI
Get started
Bicara Therapeutics Inc. Common Stock logo

Bicara Therapeutics Inc. Common Stock

BCAX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$23.90

−$0.49 · -2.01%

Aug 21, 4:00 PM ET

BCAX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

71

Gaining

Sentiment

55

Mixed

Risk resilience

65

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Claire Mazumdar Clemon
Listed since
Sep 13, 2024
Employees
103

Market position

Day range

Current $23.90

52-week range

Current $23.90

Open
$24.73
Previous close
$24.39
Volume
496.35K
0.75× average
Average volume
657.6K
Average daily volume
Market cap
1.57B USD
Beta
-0.75
Market reference 1
50-day average
$26.3639
-9.35% below average
200-day average
$20.5509
+16.30% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
825.24M USD
P/E (TTM)
-7.71×
P/B (TTM)
3.46×
P/S (TTM)
0×
EV / EBITDA
-6×
Earnings yield
-14.99%
Free cash flow yield
-11.64%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-34.36%
Return on assets
-32.01%
Return on invested capital
-38.60%

Financial health

Debt / equity
0×
Current ratio
14.58×

Financial statements

Income trends

Operating income

−155.6M USD-88.87%

Net income

−137.95M USD-102.88%
Income trends across reported periods−25.86M USD−73.04M USD−120.22M USD−167.4M USDOperating income, FY2022: −37.66M USDOperating income, FY2023: −39.89M USDOperating income, FY2024: −82.39M USDOperating income, FY2025: −155.6M USDNet income, FY2022: −37.85M USDNet income, FY2023: −51.99M USDNet income, FY2024: −68M USDNet income, FY2025: −137.95M USDFY2022FY2023FY2024FY2025
Operating income FY2022 −37.66M USD. Operating income FY2023 −39.89M USD. Operating income FY2024 −82.39M USD. Operating income FY2025 −155.6M USD. Net income FY2022 −37.85M USD. Net income FY2023 −51.99M USD. Net income FY2024 −68M USD. Net income FY2025 −137.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022
Research and development125.1M USD63.62M USD30.62M USD31.31M USD
Selling, general, and administrative30.51M USD18.77M USD9.27M USD6.34M USD
Operating expenses155.6M USD82.39M USD39.89M USD37.66M USD
Interest income17.87M USD14.58M USD1.31M USD4K USD
Interest expense———112K USD
Depreciation and amortization105K USD56K USD19K USD10K USD
Operating income−155.6M USD−82.39M USD−39.89M USD−37.66M USD
Net income−137.95M USD−68M USD−51.99M USD−37.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
25%
2 beats, 6 misses, 0 met estimates
Average EPS surprise
-49.73%
8 comparable reports
Latest EPS result
-0.82
Estimate -0.82 · Miss by 0.03%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.26-0.5-0.74-0.98Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.39, estimate -0.31, surprise -25.81%, Miss. Q2 2025, reported May 13, 2025: actual -0.68, estimate -0.4, surprise -70.00%, Miss. Q3 2025, reported Aug 12, 2025: actual -0.5, estimate -0.54, surprise +7.41%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.67, estimate -0.55, surprise -21.82%, Miss. Q1 2026, reported Mar 26, 2026: actual -0.68, estimate -0.72, surprise +5.56%, Beat. Q2 2026, reported May 11, 2026: actual -0.93, estimate -0.64, surprise -45.31%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.82, estimate -0.82, surprise -0.03%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.85, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$32.57

36.28% upside
Past 12 months12-month forecastHigh $42.00Average $32.57Low $20.00

Rating distribution

9 ratings
Strong buy00%
Buy667%
Hold333%
Sell00%
Strong sell00%

BCAX news

globenewswire.com

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,…

Read source
defenseworld.net

Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX

Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission…

Read source
seekingalpha.com

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort…

Read source
benzinga.com

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.

Read source
seekingalpha.com

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Bicara Therapeutics Q2 Earnings Call Highlights

Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or…

Read source

BCAX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BCAX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
45.44M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
28.07M
Weight
0.25%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
27.61M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
13.33M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
8.69M
Weight
0.06%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
6.88M
Weight
0.06%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
6.72M
Weight
0.04%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
4.94M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research BCAX

research.disclaimer